Scancell
CTA approval confirms H221 COVIDITY Phase I startScancell
COVIDITY programme to start Phase I in H221Scancell
H121 results highlight shift to delivery and executionScancell
Redmile funding releases the brakesScancell
Redmile endorses technologies with a further £30mScancell
UKRI awards funding for COVID-19 trialScancell
Transformational £15m capital raise closesScancell
Material fund raise means clinical progress in sightScancell
COVID 2nd generation vaccine opportunity is all upsideScancell
Reasons to be cheerful